BOSTON, MA – Kiran Mazumdar-Shaw, founder of biopharmaceutical company Biocon, has named her niece Claire Mazumdar as her successor, outlining a formal succession plan for the company, according to a ...

Bladder cancer continues to be one of the most frequently diagnosed malignancies worldwide, with current treatments such as surgery and chemotherapy often ...

SamanTree Medical announces that Histolog® Scanner confocal microscopy technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International.

A Spectra Physics Model A supermarket scanner—one of the first ten ever produced. A laser within the unit projects a beam onto a mirror that redirects it through the glass plate on the top. Cade ...

Biocon Academy, a Centre of Excellence for Advanced Learning in Applied Biosciences, hosted its 10th graduation ceremony at its Bengaluru campus, with 156 students graduating this year. Seven ...

Durvalumab shows promising results in trial led by London-based Institute of Cancer Research Doctors are hailing a drug that spares bladder cancer patients “life-changing” surgery and stops tumours ...

USD 5.5 billion deal: Biocon, an innovation-driven global biopharmaceuticals company, on Saturday, December 6 2025, announced a strategic move to fully integrate Biocon Biologics Limited (BBL) as a ...

AI can be used by consumers for basic health questions to save time spent with real-life doctors, according to Alex Zhavoronkov, CEO of Insilico Medicine. OpenAI and Amazon launched health care tools ...

Biocon Biologics established its first North American headquarters right here in the great Garden State, selecting Bridgewater as the site. The global biosimilars company announced the location this ...

These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...